Maxim Group Reaffirms Buy Rating for BeiGene, Ltd. (NASDAQ:BGNE)

Maxim Group reaffirmed their buy rating on shares of BeiGene, Ltd. (NASDAQ:BGNE) in a research note released on Monday, September 11th. They currently have a $77.00 price objective on the stock.

A number of other research analysts have also commented on BGNE. William Blair reiterated an outperform rating on shares of BeiGene in a report on Thursday, June 1st. Robert W. Baird upped their price target on BeiGene from $44.00 to $58.00 and gave the stock an outperform rating in a report on Thursday, July 6th. Morgan Stanley reiterated an overweight rating and set a $83.00 price target on shares of BeiGene in a report on Monday, July 10th. Zacks Investment Research upgraded BeiGene from a sell rating to a buy rating and set a $79.00 price target for the company in a report on Tuesday, July 11th. Finally, Ladenburg Thalmann Financial Services initiated coverage on BeiGene in a research note on Monday, August 7th. They issued a buy rating and a $81.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $77.33.

Shares of BeiGene (NASDAQ:BGNE) opened at 84.89 on Monday. BeiGene has a 52 week low of $26.43 and a 52 week high of $86.80. The company has a 50 day moving average of $77.30 and a 200-day moving average of $77.30. The company’s market cap is $3.38 billion.

TRADEMARK VIOLATION WARNING: “Maxim Group Reaffirms Buy Rating for BeiGene, Ltd. (NASDAQ:BGNE)” was published by BBNS and is the property of of BBNS. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/beigene-ltd-bgne-rating-reiterated-by-maxim-group/1634279.html.

In related news, Director Bros. Advisors Lp Baker purchased 176,056 shares of the stock in a transaction on Friday, August 11th. The shares were purchased at an average cost of $71.00 per share, for a total transaction of $12,499,976.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Xiaodong Wang sold 35,000 shares of the company’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $44.95, for a total value of $1,573,250.00. Following the completion of the sale, the director now owns 26,600 shares in the company, valued at $1,195,670. The disclosure for this sale can be found here. Insiders sold 285,210 shares of company stock valued at $18,023,500 over the last 90 days. 24.20% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in BeiGene in the second quarter valued at $111,000. Profund Advisors LLC bought a new stake in BeiGene in the second quarter valued at $248,000. Renaissance Technologies LLC bought a new stake in BeiGene in the first quarter valued at $238,000. Airain ltd bought a new stake in BeiGene in the first quarter valued at $320,000. Finally, ProShare Advisors LLC grew its position in BeiGene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock valued at $361,000 after acquiring an additional 2,918 shares during the period. Hedge funds and other institutional investors own 51.02% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with our FREE daily email newsletter.

 


Latest News

Bryce Harper Hoping to Return Monday from Knee Injury
Bryce Harper Hoping to Return Monday from Knee Injury
American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?


Leave a Reply

 
© 2006-2017 BBNS.